m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00255)
Target Name Hepatocyte nuclear factor 3-gamma (HNF3gamma/FOXA3)
Synonyms
HNF-3-gamma; HNF-3G; Fork head-related protein FKH H3; Forkhead box protein A3; Transcription factor 3G; TCF-3G; HNF3G; TCF3G
    Click to Show/Hide
Gene Name FOXA3
Chromosomal Location 19q13.32
Function
Transcription factor that is thought to act as a 'pioneer' factor opening the compacted chromatin for other proteins through interactions with nucleosomal core histones and thereby replacing linker histones at target enhancer and/or promoter sites (By similarity). Originally described as a transcription activator for a number of liver genes such as AFP, albumin, tyrosine aminotransferase, PEPCK, etc. Interacts with the cis-acting regulatory regions of these genes. Involved in glucose homeostasis; binds to and activates transcription from the G6PC1 promoter. Binds to the CYP3A4 promoter and activates its transcription in cooperation with CEBPA. Binds to the CYP3A7 promoter together with members of the CTF/NF-I family. Involved in regulation of neuronal-specific transcription. May be involved in regulation of spermatogenesis.
    Click to Show/Hide
Gene ID 3171
Uniprot ID
FOXA3_HUMAN
HGNC ID
HGNC:5023
Ensembl Gene ID
ENSG00000170608
KEGG ID
hsa:3171
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
FOXA3 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Methyltransferase-like 14 (METTL14) [WRITER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by METTL14
Cell Line mouse embryonic stem cells Mus musculus
Treatment: METTL14-/- ESCs
Control: Wild type ESCs
 GSE145309
Regulation
logFC: -4.46E+00
p-value: 6.08E-19
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary The Hepatocyte nuclear factor 3-gamma (HNF3gamma/FOXA3) reduction in hepatocellular carcinoma could be mediated by METTL14-dependent m6A methylation of HNF3-Gamma mRNA. HNF3-Gamma plays an essential role in HCC differentiation and serves as a therapeutic target and predictor of sorafenib benefit in patients.
Target Regulation Down regulation
Responsed Disease Hepatocellular carcinoma ICD-11: 2C12.02
 Disease Info 
Responsed Drug Sorafenib Approved
 Drug Info 
Cell Process Membrane transport
Cell apoptosis
In-vitro Model HCCLM3 Adult hepatocellular carcinoma Homo sapiens CVCL_6832
Huh-7 Adult hepatocellular carcinoma Homo sapiens CVCL_0336
In-vivo Model When xenografted tumor growth reached 500 mm3, the mice were subjected to intratumoral injection of Ad-con or Ad-HNF3γ every other day. For the PDX model, fresh patient HCC tissues were cut into fragments with a volume of 3 × 3 mm3 and then implanted subcutaneously into the flanks of nude mice. The mice were given sorafenib (30 mg/kg) or vehicle orally twice a week for 24 days.
Liver cancer [ICD-11: 2C12]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary The Hepatocyte nuclear factor 3-gamma (HNF3gamma/FOXA3) reduction in hepatocellular carcinoma could be mediated by METTL14-dependent m6A methylation of HNF3-Gamma mRNA. HNF3-Gamma plays an essential role in HCC differentiation and serves as a therapeutic target and predictor of sorafenib benefit in patients.
Responsed Disease Hepatocellular carcinoma [ICD-11: 2C12.02]
Target Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
Target Regulation Down regulation
Responsed Drug Sorafenib Approved
 Drug Info 
Cell Process Membrane transport
Cell apoptosis
In-vitro Model HCCLM3 Adult hepatocellular carcinoma Homo sapiens CVCL_6832
Huh-7 Adult hepatocellular carcinoma Homo sapiens CVCL_0336
In-vivo Model When xenografted tumor growth reached 500 mm3, the mice were subjected to intratumoral injection of Ad-con or Ad-HNF3γ every other day. For the PDX model, fresh patient HCC tissues were cut into fragments with a volume of 3 × 3 mm3 and then implanted subcutaneously into the flanks of nude mice. The mice were given sorafenib (30 mg/kg) or vehicle orally twice a week for 24 days.
Sorafenib [Approved]
 Drug Info 
In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response [1]
Response Summary The Hepatocyte nuclear factor 3-gamma (HNF3gamma/FOXA3) reduction in hepatocellular carcinoma could be mediated by METTL14-dependent m6A methylation of HNF3-Gamma mRNA. HNF3-Gamma plays an essential role in HCC differentiation and serves as a therapeutic target and predictor of sorafenib benefit in patients.
Target Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
Target Regulation Down regulation
Responsed Disease Hepatocellular carcinoma ICD-11: 2C12.02
 Disease Info 
Cell Process Membrane transport
Cell apoptosis
In-vitro Model HCCLM3 Adult hepatocellular carcinoma Homo sapiens CVCL_6832
Huh-7 Adult hepatocellular carcinoma Homo sapiens CVCL_0336
In-vivo Model When xenografted tumor growth reached 500 mm3, the mice were subjected to intratumoral injection of Ad-con or Ad-HNF3γ every other day. For the PDX model, fresh patient HCC tissues were cut into fragments with a volume of 3 × 3 mm3 and then implanted subcutaneously into the flanks of nude mice. The mice were given sorafenib (30 mg/kg) or vehicle orally twice a week for 24 days.
References
Ref 1 m6A RNA methylation-mediated HNF3Gamma reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance. Signal Transduct Target Ther. 2020 Dec 26;5(1):296. doi: 10.1038/s41392-020-00299-0.